{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:54Z","timestamp":1785909174714,"version":"3.56.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Objective<\/jats:title>\n \n The aim of this study was to evaluate the efficacy of 6-18F-fluoro-L-3,4-dihydroxyphenylalanine (\n 18<\/jats:sup>\n F-FDOPA) positron emission tomography\/computed tomography (PET\/CT) in the identification of primary and metastatic NETs in patients with multiple endocrine neoplasia type 1 (MEN1).\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n \n This prospective MEN1 cohort study evaluated 16 genetically confirmed patients with MEN1. Inpatient subjects were imaged using CT, magnetic resonance imaging (MRI),\n 68<\/jats:sup>\n Ga-DOTATATE PET\/CT, and\n 18<\/jats:sup>\n F-FDOPA PET\/CT. A composite reference test combining up to 3 years of historical imaging and a multidisciplinary evaluation was used against the index test. Lesion-, patient-, and site-based analyses were performed.\n <\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n The NIH Clinical Center was the setting for this study.<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n \n Patients with germline\n MEN1<\/jats:italic>\n variants confirmed to have MEN1 were included in the study.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 134 lesions were identified after review of CT, MRI, and\n 68<\/jats:sup>\n Ga-DOTATATE PET\/CT.\n 18<\/jats:sup>\n F-FDOPA PET\/CT detected 17% (23\/134, 95% CI: 8.2\u201327.1). Of the total study participants, 50% (8\/16) of the patients had\n 18<\/jats:sup>\n F-FDOPA PET\/CT uptake in primary and metastatic sites with overlapping\n 68<\/jats:sup>\n Ga-DOTATATE PET\/CT uptake and localization on CT and MRI. Region-based analysis showed that\n 18<\/jats:sup>\n F-FDOPA PET\/CT had the highest avidity for lung (4\/12, 33%) and pancreatic (8\/38, 21%) NETs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n 18<\/jats:sup>\n F-FDOPA PET\/CT has low efficacy overall in detecting MEN1-related NETs.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n https:\/\/clinicalstudies.info.nih.gov\/protocoldetails.aspx?id=000344-DK&amp;&amp;query=<\/jats:ext-link>\n , identifier NCT04969926.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1849746","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:41:59Z","timestamp":1785908519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDOPA PET\/CT for neuroendocrine tumors in multiple endocrine neoplasia type 1"],"prefix":"10.3389","volume":"17","author":[{"given":"Aisha A.","family":"Tepede","sequence":"first","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Lee","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Welch","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Mandl","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Cochran","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamimi","sequence":"additional","affiliation":[{"name":"Biomedical and Metabolic Imaging Branch\/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Simonds","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Gharib","sequence":"additional","affiliation":[{"name":"Biomedical and Metabolic Imaging Branch\/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Millo","sequence":"additional","affiliation":[{"name":"Clinical Center PET Department (CC PET), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira M.","family":"Sadowski","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute (NCI), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Blau","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Jha","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-009-0290-1","article-title":"Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients","volume":"34","author":"Goudet","year":"2010","journal-title":"World J Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"926491","DOI":"10.1530\/endoabs.81.yi11","article-title":"Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice","volume":"13","author":"van Beek","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121937","article-title":"Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: A comprehensive analysis in the era of somatostatin receptor PET imaging","volume":"17","author":"Maratta","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: Imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s2213-8587(25)00119-6","article-title":"Multiple endocrine neoplasia type 1 (MEN1): Recommendations and guidelines for best practice","volume":"13","author":"Brandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","article-title":"Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET","volume":"45","author":"Becherer","year":"2004","journal-title":"J Nucl Med"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1148\/radiology.220.2.r01au25373","article-title":"Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors","volume":"220","author":"Hoegerle","year":"2001","journal-title":"Radiology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3833-y","article-title":"Quantitative (18)F-DOPA PET\/CT in pheochromocytoma: The relationship between tumor secretion and its biochemical phenotype","volume":"45","author":"Amodru","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00087","article-title":"Diagnosing nonfunctional pancreatic NETs in MEN1: The evidence base","volume":"2","author":"van Treijen","year":"2018","journal-title":"J Endocr Soc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(06)70801-4","article-title":"Staging of carcinoid tumours with 18F-DOPA PET: A prospective, diagnostic accuracy study","volume":"7","author":"Koopmans","year":"2006","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/edm-19-0156","article-title":"18F-FDOPA PET\/CT accurately identifies MEN1-associated pheochromocytoma","volume":"2020","author":"Tepede","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-1030-8","article-title":"Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours","volume":"36","author":"Haug","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000002202","article-title":"18F-FDOPA uptake reflects the efficacy of dopamine agonists treatment in pituitary prolactinoma","volume":"43","author":"Heimburger","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1357","article-title":"Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia","volume":"95","author":"Tessonnier","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ando.2019.11.001","article-title":"Comparison of 68Ga-DOTATATE PET\/CT and 18F-FDOPA PET\/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient","volume":"81","author":"Jullien","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.126896","article-title":"18F-fluorodihydroxyphenylalanine PET\/CT in patients with neuroendocrine tumors of unknown origin: Relation to tumor origin and differentiation","volume":"55","author":"Imperiale","year":"2014","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/cen.14527","article-title":"Head-to-head comparison between (18) F-DOPA PET\/CT and (68) Ga-DOTA peptides PET\/CT in detecting intestinal neuroendocrine tumours: A systematic review and meta-analysis","volume":"95","author":"Piccardo","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s2213-8587(25)00300-6","article-title":"Adrenal tumour imaging: Clinical, molecular, and radiomics perspectives","volume":"14","author":"Pacak","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf114","article-title":"Prospective evaluation of 68Ga-DOTATATE and 18F-DOPA PET scans in detecting tumors causing ectopic ACTH syndrome","volume":"110","author":"Elenius","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9465-0","article-title":"Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors","volume":"19","author":"Pedraza-Ar\u00e9valo","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030501","article-title":"Somatostatin-dopamine chimeric molecules in neuroendocrine neoplasms","volume":"10","author":"Cantone","year":"2021","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02754","article-title":"68Ga-Exendin-4 PET\/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1","volume":"104","author":"Antwi","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/eje-16-1079","article-title":"Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-avid tumor volume measurements","volume":"176","author":"Tirosh","year":"2017","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1849746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:42:00Z","timestamp":1785908520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1849746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1849746"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1849746","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1849746"}}